Revvity delivered a solid second-quarter performance with total revenue reaching $711 million, marking 3% organic growth for the period. This result was primarily fueled by an 11% organic expansion in the Diagnostics segment, which offset a slight decline in Life Sciences. Capitalizing on accelerating demand from pharmaceutical and biotech customers—particularly for AI-driven science tools—the company raised its full-year organic growth guidance to 4-5% from the previous 3-4% range. Additionally, Revvity increased its adjusted earnings per share (EPS) outlook to $5.30-$5.40, up $0.10 from prior estimates, signaling strong operational momentum and improved market conditions.

The financial results were bolstered by exceptional cash flow generation, with free cash flow reaching $184 million in the quarter, representing a 117% conversion rate of adjusted net income. Management highlighted that approximately half of the adjusted EPS upside was derived from $16 million in tariff-related refunds received during the quarter. Despite these one-time benefits, pro forma adjusted operating margins remained above the 27% guidance assumption, demonstrating underlying operational strength. The company also retired a €500 million note in mid-July, reducing gross leverage and positioning net leverage to approach two times by year-end.

Segment Performance

The Diagnostics segment emerged as the primary growth engine, generating $352 million in revenue, up 11% organically. This broad-based strength was led by reproductive health, which grew in the mid-teens, and immunodiagnostics outside China, which accelerated into high single digits. Conversely, the Life Sciences segment reported revenue of $359 million, declining 3% organically. This dip was largely attributed to a ~20% drop in the Signals software business due to difficult year-over-year comparisons and contract timing. However, management expects Signals to return to double-digit growth in the second half of the year, supported by new offerings like Signals AI and the Anthropic MCP connector.

Strategic Divestiture and AI Momentum

Revvity signed a definitive agreement to divest its China immunodiagnostics business, with closure expected by the end of 2027. This move aims to sharpen focus on core markets where the company generates higher returns, as China has presented structural challenges for this specific business unit. All non-GAAP metrics and guidance provided are on a pro forma basis, excluding this divested business.

What the Numbers Show

A critical divergence exists between top-line growth and software performance, highlighting a transition phase in Revvity’s portfolio. While overall organic growth is positive at 3%, the Life Sciences segment’s decline is almost entirely isolated to the Signals software business (-20%). However, this contraction is counterbalanced by robust demand for hardware instruments, particularly the Opera Phenix OptiQ, which saw double-digit order growth. The resulting instrument backlog is at its strongest level in three to four years, suggesting that the current software slowdown is temporary and likely to reverse in H2 as new AI-integrated features drive renewed adoption.

Looking ahead, Revvity expects third-quarter organic growth to range between 4% and 6%, with revenue projected between $685 million and $700 million. The company anticipates pro forma adjusted operating margins of approximately 29% for Q3, maintaining its commitment to reinvesting tariff refunds into strategic initiatives, supply chain enhancements, and talent acquisition to capitalize on the emerging AI-driven discovery workflow.

Revvity, Inc. (NYSE: RVTY) has declared a regular quarterly dividend of $0.07 per share of common stock, signaling its ongoing commitment to shareholder returns. The Board of Directors approved the payout, which will be distributed to all shareholders of record at the close of business on October 23, 2026. This declaration underscores the company's stable financial position and its strategy to provide consistent income to its investor base.

The dividend is payable on November 13, 2026. Shareholders must hold the company's common stock by the record date to be eligible for the payment. The Board of Directors determined that this distribution aligns with the company's current cash flow generation and future capital requirements.

Dividend Details

Company Overview

Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics. With approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech sectors, diagnostic labs, academia, and governments in more than 160 countries. The company reported revenue of $2.9 billion in 2025 and is part of the S&P 500 index.